GenrAb — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

GenrAb is a private, preclinical-stage biotech leveraging its proprietary Antibody Gene Signature (AGS) platform to discover fully human, neuroprotective monoclonal antibodies from patients with neurological disorders. The company's lead candidate, TGM-010, targets a conserved neurodegenerative pathway and has shown efficacy in reducing disability in preclinical models, with a pipeline of over 400 identified mAbs. GenrAb is addressing a significant unmet need in neurology, as there are currently no approved disease-modifying neuroprotective therapies on the market, positioning itself to potentially treat a range of conditions like ALS, Alzheimer's, Parkinson's, and Multiple Sclerosis.

NeurologyNeurodegenerative Diseases

Technology Platform

Antibody Gene Signature (AGS) technology; an immune-centric drug discovery platform that mines the human immune repertoire from patients with neurological disorders to identify rare, naturally occurring, fully human, neuroprotective monoclonal antibodies.

Opportunities

The primary opportunity is addressing the vast, unmet need for neuroprotective therapies in major neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's, which represent multi-billion dollar markets.

The broad-spectrum potential of its lead candidate, TGM-010, could allow it to target multiple indications with a single asset, maximizing value.

Success would validate its novel AGS platform, creating a pipeline engine for future antibody discoveries.

Risk Factors

Key risks include the high scientific and translational risk of moving a novel neuroprotective agent from preclinical models to successful human trials, an area with a history of late-stage failures.

As a private, preclinical company, it faces significant funding risk and dilution.

There is also platform risk if the AGS technology fails to consistently produce viable clinical candidates beyond its initial successes.

Competitive Landscape

GenrAb operates in the highly competitive neurodegenerative disease space, competing with large pharma and biotech firms exploring a wide range of mechanisms (e.g., anti-amyloid, anti-tau, gene therapies). Its key differentiation is its focus on naturally derived, fully human neuroprotective antibodies targeting conserved pathways, a niche with few direct competitors. However, it must prove its approach is superior or complementary to other disease-modifying strategies in development.

More companies in Biologics / Biosimilars →More companies in United States →